Advanced non-small cell lung cancer in elderly patients: A review

doi:10.5320/wjr.v5.i2.102

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7021)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-7) series.

Item

Count

PDF

387

WORD

221

HTML

3064

Tables (1-7)

344

Sum=4016

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1146

Download

1859

Sum=3005

Jul 28, 2015 (publication date) through Feb 11, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Respirology

ISSN

2218-6255

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Respirol. Jul 28, 2015; 5(2): 102-111
Published online Jul 28, 2015. doi: 10.5320/wjr.v5.i2.102

Table 6 Studies with gefitinib (250 mg/d) plus chemotherapy in the treatment of elderly patients (age ≥ 70 years) with advanced non-small-cell lung cancer

Ref.	Treatment	Study phase	No. of patients	RR (%)	SD (%)	MST (mo)	Toxicity G ≥ 3
Stinchcombe et al[63]	TXT 30-36 mg/m², days 1, 8, 15, Q4W	I/II	26	8 (31)	-	6.5	G3-5 toxicity
Stinchcombe et al[63]	TXT 30-36 mg/m², days 1, 8, 15, Q4W	I/II	26	8 (31)	-	6.5	42%
Bepler et al[64]	TXT 75 mg/m², day 1, Q3W	II	21	8 (38)	5 (24)	12.4	G3-4 toxicity 28.5%
Scagliotti et al[65]	GEM 1200 mg/m², days 1, 8, Q3W	II Random	35	2 (5.7)	14 (40)	9.1	G3-4 neutropenia 11.4%
	vs
	VNR 30 mg/m², days 1, 8, Q3W		25	0 (0)	11 (44)	12.2	G3-4 neutropenia 72%
	VNR 30 mg/m², days 1, 8, Q3W						3 toxic deaths

RR: Response rate; SD: Stable disease; MST: Median survival time; G: Grade; TXT: Docetaxel; GEM: Gemcitabine; VNR: Vinorelbine; Q4W: Every 4 wk; Q3W: Every 3 wk; Random: Randomised.

Citation: Buffoni L, Consito L, Filippi AR, Ruffini E, Solidoro P, Bironzo P, Satolli MA, Schena M, Ciuffreda L. Advanced non-small cell lung cancer in elderly patients: A review. World J Respirol 2015; 5(2): 102-111
URL: https://www.wjgnet.com/2218-6255/full/v5/i2/102.htm
DOI: https://dx.doi.org/10.5320/wjr.v5.i2.102